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“The pharmaceutical industry is under extreme 
financial pressure…Given increasingly cost-
constrained health care systems, limited patent 
durations on blockbuster drugs, competition from 
generics, a more demanding regulatory environment, 
diminishing marketing exclusivity, and progressively 
smaller markets resulting from the rapidly increasing 
molecular segmentation of the populations of 
patients…companies are being forced to overhaul their 
drug development strategies. A9B 
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A. Biopharma industry is significantly disrupted by genomics 
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B. Intellectual property (IP) strengthens the value of 
exclusivity amidst rising development costs 
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C. No revenue, development stage biotech firms face 
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Gene therapy products now have the potential to cure 
intractable diseases, and fundamentally alter the 
trajectory of many other vexing illnesses. To advance 
these opportunities, the FDA plans to introduce 
additional new policy guidance and other advances in 
our drug development framework in 2019. Today, we 
want to take an opportunity to preview that policy 
agenda and offer some perspective on the focus of our 
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